A director at Omnicell Inc bought 10,561 shares at 33.129USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
OMNICELL (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date February 23, 2021, the closing price was USD 130.05 a...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Allegheny General Hospital, Pittsburgh, Pa., part of Allegheny Health Network (AHN), has selected Omnicell’s Central Pharmacy IV Compounding Service, a comprehensive, turnkey approach for insourcing some sterile compounding operations. Nearly one out of ten IVs are not prepared within guidelines1 using manual processes and contamination is one of the most frequent errors2. Omnicell’s Central P...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2019. GAAP Results GAAP revenues for the second quarter of 2019 were $217.4 million, up $28.7 million, or 15.2% from the second quarter of 2018. GAAP revenues for the six months ended June 30, 2019 were $419.9 million, up $48.6 million, or 13.1%, from the six months ended June 30, 2018. Second quarter 2019 GAAP net income as reported was $16.0 m...
Key Points: • The U.S. dollar is breaking its 16-month uptrend and is declining through its 200-day moving average and Gold is breaking to 6-year price highs. RS appears to be staging a reversal at a support level. (ex. GC00, GDX) • A number of Healthcare Sector names are breaking out or staging reversals. (ex. ITGR, CHE, XRAY, OMCL, MOH, WCG, ARWR, INCY, GILD, VRTX, IQV, MEDP, and CTLT)
Key Points: • Gold is staging a massive breakout above the $1360 level. Major H&S bottoms can be seen across the group (ex, NEM, RGLD) • Energy related names are attempting to carve out reversals. We prefer the names that held up well during the Crude oil decline. (ex. HLX, PUMP, FTI, CKH, PSX) • A number of Biotech names are breaking out of bases and reflect RS leadership. (ex. OMCL, RGEN, INCY, and ANIP)
Key Points: • The Staples Sector continues to develop positive price and RS reversals. • A number of Insurance related names are breaking to new price and RS highs. • Semis and Semi-Suppliers continue to weaken. We highlighted Semi-Suppliers in March as showing top patterns; many are breaking to 52-week lows. • Many Energy E&P stocks are developing top patterns.
Key Points: • Property & Casualty Insurance names are staging price and RS reversal and/or breakouts. • Airlines are staging price and SR reversals to the upside and/or are breaking out. • Railroad related names are breaking out. • We have been bearish on much of the Semiconductor and Suppliers industry since February; however we are seeing some near term reversals at support levels. We will keep you posted of any further changes.
Key Points: • We are upgrading Health Care to an overweight. XLV is breaking topside a bullish base and reversing a 9-month RS downtrend. • Biotechs are leadership and are breaking out of bullish consolidation. XBI and IBB are constructive and making positive inflections. • Energy remains a leadership Sector with many bullish bases that are still unexploited. We have highlighted a number of them in today's Vital Signs.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.